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Abstract. The localization of a radiolabeled murine mono- 
clonal antibody reactive with choriocarcinomas to human 
choriocarcinoma xenografts following intravenous and sub- 
cutaneous injection was evaluated by gamma scanning and 
tissue sampling. Tumor xenografts were established in the 
popliteal node region of athymic nude mice after repeated 
innoculations of the hind foot pads with BEWO choriocar- 
cinoma cells. In dual label specific antibody studies, tumor/ 
non tumor uptake ratios following subcutaneous (resulting 
in considerable intralymphatic uptake) injection of 131I- 
5F9.3 were significantly higher than those achieved post 
simultaneous intravenous injection of ~25I-5F9.3. Double 
label experiments with 131I-5F9.3 and a nonspecific anti- 
body, 125I-UPC-10, following subcutaneous injection, dem- 
onstrated that the high localization to popliteal region tu- 
mors was largely due to antibody specificity. Gamma scans 
following subcutaneous antibody administration of specific 
antibody to tumor bearing animals showed tumors soon 
after subcutaneous injection, at times earlier than those typ- 
ically seen following intravenous delivery. Similar subcuta- 
neous injections showed little normal nodal uptake in 
BALB/c control animals on gamma scans. No correlation 
was seen between tumor localization by specific antibody 
between the intravenous and intralymphatic routes, imply- 
ing a difference in the mechanisms of tumor uptake of anti- 
body by these two routes. The subcutaneous approach to 
antibody delivery offers advantages over intravenous deliv- 
ery in tumors of human origin, including higher tumor/non 
tumor ratios and earlier imaging times. This was true even 
though these tumors were many times larger than normal 
lymph nodes. This subcutaneous delivery advantage should 
be exploitable in imaging nodal metastases of human tu- 
mors. 
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The compelling concept of specific delivery of radionuclides 
to tumors for purposes of diagnosis and therapy has neared 
reality with the availability of monoclonal antibodies reac- 
tive with tumor associated antigens. While antibody local- 
ization to tumors following intravenous injection of ra- 
dioantibody has been high enough in some instances to 
be useful diagnostically, relatively low tumor/non tumor 
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ratios have often necessitated the use of background sub- 
traction techniques (Goldberg et al. 1978) or antibody frag- 
mentation (Wahl et al. 1983). While these techniques are 
useful, higher tumor/non tumor ratios are desirable. 
We have faced these problems both clinically and in 
laboratory animals in radioimmunodetection studies of 
choriocarcinomas of testicular and trophoblastic origin. In 
studies using 1311 murine monoclonal antibody 5F9.3, reac- 
tive with choriocarcinomas and testicular carcinomas, tu- 
mor to background ratios higher than those of nonspecific 
antibody are achieved, but are still relatively low (Khazaeli 
et al. 1983; Wahl et al. 1987). While we have recently en- 
hanced tumor visualization in patients through the use of 
a computer aided cinematic background display system, 
higher tumor/non tumor ratios would further enhance diag- 
nostic accuracy (Wahl et al. 1986). 
In the mid and late 1970's, radiolabeled polyclonal anti- 
bodies were used for tumor detection in patients following 
subcutaneous delivery (DeLand et al. 1980; Order etal.  
1975). These studies showed potential, but concern was rais- 
ed regarding the tumor shedding antigen, possibly resulting 
in false positive scan results (DeLand et al. 1980). More 
recently, Weinstein and coworkers demonstrated the value 
of subcutaneous antibody delivery, showing preferential up- 
take of specific antibody to tumor metastases in regional 
lymph nodes draining the site of the labeled antibody injec- 
tion, due largely to antibody specificity (Weinstein et al. 
1983). Improvement was demonstrated over the intrave- 
nous delivery route, however the tumor system studied used 
was not of human origin (Weinstein et al. 1983). 
A murine monoclonal antibody reactive with BEWO 
choriocarcinoma as well as with non seminomatous testicu- 
lar tumors has been developed (5F9.3) and shown capable 
of specific localization, (when radiolabeled), to xenografts 
of this tumor following intravenous administration in ani- 
mals and humans (Khazaeli et al. 1983, 1987; Patillo et al. 
1968, 1984). In this study we evaluated by dual label tissue 
distribution studies and external gamma scanning, whether 
subcutaneously administered (presumedly coursing largely 
intra-lymphatically) monoclonal antibodies reactive with a 
human choriocarcinoma tumor, would preferentially local- 
ize to tumors of human histology, produced by introducing 
single cell suspensions of this choriocarcinoma cell line 
(BEWO) into the foot pad region of nude mice resulting 
in the growth of such tumors in the popliteal fossa nodal 
region. If improved antibody localization to this tumor 
could be demonstrated following subcutaneous injection, 
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then this delivery approach may have clinical relevance in 
humans, particularly since nodal metastases are common 
in testicular tumors. 
Materials and methods 
Cell line. BEWO choriocarcinoma cells were a generous 
gift of  Dr. R. Patillo and were maintained in tissue culture 
at 37 ° C in the presence of 5% CO2 in RPMI 1640 with 
10% fetal calf serum and 2 mm 2 ME. Cells for animal 
inoculations were removed with 0.5% trypsin (Patillo et al. 
1968). 
Monoclonal antibody. The production of the monoclonal 
antibody 5F9.3 has been described elsewhere (Khazaeli 
et al. 1983, 1987; Patillo et al. 1984). In brief, this murine 
IgG antibody was raised against embryonal cell carinoma 
of the testis (following immunizations with fresh and frozen 
patient cancer cells) and shares reactivity with an antigen 
expressed on several choriocarcinoma cell lines including 
the BEWO line. The antibody was purified from ascites 
grown in BALB/c mice by staphylococcal protein A chro- 
matography. Purity was confirmed by 7.5% SDS PAGE 
gels (Laemmli 1970). The control monoclonal antibody, 
UPC-10, was purchased from Litton Bionetics. 
Animal model. Three-to 6-week-old female nu/nu BALB/c 
mice (Charles River) were inoculated using a sterile tech- 
nique in each of the hind foot pads with 5-10 million viable 
BEWO choriocarcinoma cells in 100 gl or less of RPMI 
1640. Repeat inoculations were given each two to four 
weeks. Animals were followed closely for signs of tumors, 
especially in the popliteal node region and selected for ex- 
periments when such tumors were palpable. Control BALB/ 
c mice (standard white mice) were purchased from Charles 
River at ages three to five weeks and received no tumor 
cell injections. 
Antibody labeling. Was conducted using the iodobead meth- 
od (Pierce), using 2 beads with 1 mCi of 131I or 125I (New 
England Nuclear) and 50 gg of either antibody (Markwell 
1982). Labeling efficiencies were in the 45%-80% range, 
with separation of labeled antibody from free iodine using 
biogel P60 chromatography. Labeled and unlabeled anti- 
body were compared for binding efficacy to BEWO target 
cells using the radiolabeled staphylococcal protein-A bind- 
ing technique (LoBuglio et al. 1983). 
Tissue localization and imaging studies. Animals were se- 
lected for imaging and radiolocalization studies when their 
tumors became palpable. Animals with these tumors were 
then injected with five to ten gCi of 13aI-5F9.3 in the foot 
pad ipsilateral to the popliteal fossa with tumor, and simul- 
taneously with five to ten gCi of a25I-5F9.3 intravenously 
by tail vein. This represented a protein dose of approximate- 
ly 1 gg by each route. Animals were imaged 4, 24, 48 and 
72 h postinjection, using a large field of view gamma camera 
with a 20% window centered at the 13~I/364 KeV photo- 
peak. The camera was equipped with a 5 mm pinhole colli- 
mator. Images were obtained for approximately 
15000 counts, for a known period of time. Pentobarbital 
(1-2 mg IP) was used as the anesthetic. Image data was 
collected into a dedicated nuclear medicine computer (MDS 
A 2) using a 64 x 64 word matrix, and stored on magnetic 
tape. Analogue images were also acquired. In other experi- 
ments, 131I-5F9.3 and a nonspecific antibody, 125I-UPC-10, 
were simultaneously injected into the foot pad with the 
above approach to imaging undertaken. 
Animals were killed at 72-96 h postinjection by asphyx- 
iation. Tissues were removed for analysis of  radioactive an- 
tibody uptake, weighed after blotting, dual energy counted 
in a gamma camera (at 1251 and i311 windows), and injected 
doses/g of tumor and normal tissue (normalized to an ani- 
mal weight of 1 kg) were determined after correction for 
spill over from 13~I to ~25I and physical decay rates (Wahl 
et al. 1983, 1984). Statistical analysis was by the students-t, 
paired-t, and analysis of variance methods. 
Results 
Animal model 
The frequency of tumor induction following injections of 
the BEWO tumors via the foot pad was much lower than 
when a comparable number of  cells was given subcutane- 
ously in the shoulder region. In the latter case, virtually 
all of  the animals innoculated with ten million cells devel- 
oped tumors. By the foot pad route, even after repeated 
injections (2-4 times), only about 30% of the animals devel- 
oped tumors in the popliteal fossa region. In no case did 
the animals develop tumors at the injection site in the foot- 
pad. The tumors from the footpad injections, when allowed 
to grow for some time, would eventually begin to invade 
the leg above and below the popliteal fossa region. The 
pathology of these tumors was choriocarcinoma. The detec- 
tion of the tumors was superior by palpation than by visual 
examination, but was difficult if they were less than 100 mg 
in size. Even in a relatively small popliteal region tumor, 
resected when it had just become palpable, definite lym- 
phoid elements were seen (implying it began in a lymph 
node), however no residual recognizable nodal architecture 
was seen (Fig. 1). The mean tumor size in our experiments 
was 200 rag. By contrast, the mean size of popliteal lymph 
nodes in normal BALB/c mice is approximately 1 mg (based 
on 6 determination). 
[ntralymphatic imaging in control animals 
To determine the scintigraphic and quantitative biodistribu- 
tion of 13q-5F9.3 injected into the subcutaneous tissues 
of the foot pad, healthy BALB/c mice were injected with 
7.5 ~tCi of 131I-5F9.3 via the foot pad and imaged to 72 h. 
These animals were also injected with 125I-5F9.3 via the 
tail vein at the beginning of the study. Animals were killed 
and tissue distributions determined using standard dual 
window counting techniques (Wahl et al. 1983, 1984). Fig- 
ure 2 (a, 24 h postinjection; b, 60 h postinjection) demon- 
strates the typical scan appearance of antibody clearance 
following injection of the hind foot pad of these healthy 
mice with ~3~I-5F9.3 antibody. Activity is initially concen- 
trated at the injection site in the foot, and gradually moves 
up the leg into the rest of the body. By 60 h after injection 
activity is seen only in the animal's body. No focal areas 
of intense uptake are seen to suggest high level sequestration 
by normal nodes in the popliteal fossa (arrows). In the ani- 
mals killed 72 h postinjection, the blood and the foot pad 
where the injection was made retained the most activity 
(Table l). The foot pad injected is, not unexpectedly, signifi- 
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Fig. 1. Foci of lymphocytes (arrow) are seen in this choriocarcin- 
oma tumor removed from the popliteal fossa. No normal nodal 
architecture is seen, despite this tumor focus being situated in the 
popliteal fossa 




Blood 0.096 ± 0.027 0.148 + 0.024 
Liver 0.016 _ 0.001 0.027 ± 0.003" 
Muscle 0.02 _+0.006 0.02 ±0.005 
Right foot pad (inj) 0.134±0.051 b 0.028_+0.001 a 
Left foot pad (non inj) 0.021 + 0.008 0.036 + 0.014 a 
Mean uptakes ± SEM in group (n = 5) of BALB/C (standard white 
laboratory) mice given 7.5 gCi ~alI-5F9.3 via foot pad (intralym- 
phatic) and 7.5 gCi ~2sI-5F9.3 intravenously via tail vein. Animals 
were killed 72 h postinjection 
" Tissue activity following intravenous administration is signifi- 
cantly different (P<0.05) than corresponding activity following 
intralymphatic injection 
b Significantly higher than left foot pad following intralymphatic 
injection, P < 0.01 
cantly more radioactive than the contralateral uninjected 
foot pad ( P <  0.01). The 5F9.3 ant ibody given intravenously 
resulted in significantly higher ( P <  0.05) liver uptake than 
the ~ same quanti ty of the ant ibody given intralymphatically. 
Blood levels in the intravenously injected group also tended 
to be higher at this time (0.05 < P < 0.1). 
Liver/blood ratios were comparable between 125I and 
131I labeled 5F9.3, suggesting that the antibodies has sinai- 
Fig. 2. a Prone view of BALB/c control animal 24 h postinjection 
subcutaneously of ~31L5F9.3 into right foot pad shows foot pad 
injection site clearly as well as whole body activity. Note the lack 
of uptake in the normal popliteal fossa (N-arrow). b Sixty hours 
postinjection subcutaneously of 13~I-5F9.3 to this normal BALB/c 
animals right foot pad is nearly devoid of activity although consid- 
erable systemic activity is present. Again note the lack of uptake 
in the normal popliteal fossa (N-arrow). e In this dorsal view of 
a BeWo tumor bearing nude mouse injected subcutaneously with 
~31I-5F9.3 in both foot pads, note activity in the foot pads, as 
well as the right popliteal fossa region tumor (T-arrow) on a view 
4 h postinjection, d Uptake to a left popliteal node region BeWo 
tumor (T-arrow) is seen just 5 h postinjection x 3 ~I-5F9.3 subcutane- 
ously to the foot pad. Free iodine activity is seen in the stomach 
and bladder of this animal imaged in the prone position, e In 
another nude mouse less striking uptake is noted into a popliteal 
fossa BeWo tumor 27 h postinjection subcutaneously into the ±psi- 
lateral foot pad shows the BeWo tumor focus activity (T-arrow), 
foot pad and whole body. Contrast this appearance to Figs. 2a 
and b. f In the same animal as e, note 48 h postinjection, the 
intense uptake in the right leg (T-arrow) (a tumor focus was identi- 
fied weighing 140 rag) as well as in a large tumor (T-arrow) in 
the left leg seen as a cold defect 4 h post antibody injection. This 
larger tumor weighed 1.1 g when the animal was killed 
lar biologic behaviors, once they reached the circulation, 
with a mean liver/blood ratio of 0.174 by intralymphatic 
delivery and 0.184 by intravenous delivery (P = NS). 
Comparison of  simultaneous intralymphatie 
and intravenous specific antibody delivery 
to popliteal regional tumors 
Ten animals with popliteal fossa tumors were selected for 
injection of 131I-5F9.3 to the foot pad ipsilateral to the 
popliteal fossa with tumor. These same animals were simul- 
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Fig. 3. Demonstrates tumor/blood ratios for subcutaneously ad- 
ministered 5F9.3 (131I label) vs intravenously administered 5F9.3 
(~2sI label). The mean tumor/blood ratio by subcutaneous (intra- 
lymphatic) injection is 2.69_+ 0.71 and the mean tumor/blood by 
intravenous is 0.92 ± 0.11. These are significantly different at P < 
0.025. Note the lack of correlation between tumor/blood ratios 
achieved by the two routes 
taneously injected intravenously with ~25I-5F9.3 in the tail 
vein. These animals were imaged at the 131I photopeak 
at several time points (generally 4, 24, 48 and 72 h postinjec- 
tion), and were killed and dual-energy tissue counted at 
72 h postinjection. In one animal, an injection of ~31I-5F9.3 
was made to each foot along with the intravenous injection, 
as one examiner clinically suspected tumor in both popliteal 
fossae. Eight of the animals survived to 72 h postinjection. 
One died at 48 h and one at 5 h post antibody injection 
as a result of anesthesia complications. Seventy two hour 
intralymphatic and intravenous delivery mediated tumor/ 
blood ratios are shown for each animal in Fig. 3. The mean 
intralymphatic/intravenous route specific localization ratio 
normalized to blood (tumor IL/blood IL)/ ( tumorIV/  
blood IV) is 3.09 + 0.96 (SEM). The intralymphatic/intrave- 
nous route specific localization ratio normalized to liver 
(tumor IL/liver IL)/(tumor IV/liver IV) ratios is 2.87_+ 0.98 
(SEM) (data not shown). Both numbers are significantly 
greater than ] ( P <  0.05) indicating that the intralymphatic 
route of delivery was superior to the intravenous route. 
Figure 3 shows the tumor/blood ratios for individual ani- 
mals achieved by the intralymphatic route as compared to 
the intravenous route in the same animals. These plots are 
of particular interest as there is no correlation seen between 
tumor/blood or tumor/liver (data not shown) ratios 
achieved by the intravenous route and those achieved by 
the intralymphatic route. Thus, an animal with a high tu- 
mor/blood ratio by intralymphatic delivery might have a 
relatively low tumor/blood ratio by intravenous delivery. 
Mean tissue uptakes (% kg injected dose/g) for ~31I-5F9.3 
given by the intralymphatic route and intravenously are 
shown in Table 2. Of note is that tumor uptake of 131I- 
5F9.3 by the intralymphatic route was 0.177_+0.081 vs. 
0.099_+ 0.017 for lZSI-5F9.3 by the intravenous route ( P =  
NS). Much as was the case in the control animals, these 
tumor bearing animals had significantly lower uptake of 
the 5F9.3 antibody in liver and blood by the intralymphatic 
route than the intravenous route which accounted for the 
superior tumor/non tumor ratios in the intralymphatic 
group. 
Table2. Organ uptakes postintralymphatic 131I-5F9.3 injection 
and simultaneous intravenous 12sI-5F9.3 injection 
131I-5F9.3 (IL) 125I-5F9.3 (IV) 
Tumor 0.177 ± 0.081 0.099 ± 0.017 
Blood 0.056 + 0.012 0.116_+ 0.02" 
Liver 0.013 ___ 0.002 0.027 -+ 0.002 b 
Mean % kg injected dose/g_+ SEM (n = 8) 
a Tissue activity following intravenous injection is significantly 
greater than intralymphatic injection at P < 0.005 
b Tissue activity following intravenous injection is significantly 
greater than intralymphatic injection at P< 0.0005 
131I and 12sI-5Fg.3 have comparable binding in vitro to BEWO 
(chorio-carcinoma) target cells 
The intralymphatic delivery route showed clear superi- 
ority over the intravenous route in tumor/non tumor ratios 
despite there being some variability among animals. Also 
observed was variability of uptake within individual tumors 
as in 1 case with a large tumor (approximately l g) a central 
necrotic region had a tumor/liver=13.3/1 while its more 
viable center had a tumor/liver of 25.6/1. 
Imaging studies reflected the higher tumor/non tumor 
ratios achieved following subcutaneous injection. In 
Fig. 2d, uptake is seen into a popliteal region tumor (arrow) 
just 4.5 h after antibody injection. In another animal shown 
in Fig. 2c and 2f, uptake is seen in both feet soon after 
injection (4 h) as well as in the popliteal lymph node region 
on the right (arrows- Fig. 2c) (animals are imaged prone). 
By 48 h (Fig. 2t) uptake is seen clearly in the right popliteal 
node region (arrow), as well as now being seen in a large 
tumor focus in the left leg (arrows). The tumor on the left 
in this animal weighed 1.1 g, while the tumor on the right 
weighed only 140 mg. Of note is that the normal popliteal 
lymph nodes in BALB/c mice weigh only 1 rag, (mean of 
excisions of 6 nodes from healthy animals). Figure 2e shows 
less striking uptake of antibody into tumor (arrow) 27 h 
postinjection into the left foot pad of another mouse with 
a popliteal fossa tumor. Note the activity in the mid leg 
representing tumor, as well as the bladder and whole body 
activity. This in contrast to the lack of midleg activity in 
the control mice in Fig. 2 a and b. 
Localization following foot pad antibody injection 
in tumor-bearing mice (specific vs non-specific antibody) 
Five nude mice bearing BEWO tumors in their popliteal 
fossae received a double label injection mixture composed 
of 5 gCi 13q-5F9.3 and 5 gCi 125I-UPC-10 nonspecific an- 
tibody (approximately 1 txg of each antibody) in the foot 
pad of the leg ipsilateral to the politeal fossa tumor. The 
animals were killed 96 h postinjection. Tumor/non tumor 
ratios were calculated for the specific and nonspecific anti- 
bodies. As can be seen in Table 3, tumor uptake of specific 
antibody given by the intralymphatic route is significantly 
greater (P<0.025) than tumor uptake of nonspecific anti- 
body administered by the same route. This high tumor up- 
take of specific antibody is in spite of uptake in other tissues 
showing the nonspecific antibody to have achieved signifi- 
cantly higher systemic levels of activity (P<0.01). Tumor/ 
non tumor ratios are shown graphically in Fig. 4 and indi- 
cate the considerable improvement in tumor accretion due 
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Table 3. Organ uptakes post dual label subcutaneous administra- 
tion 
~31I-5F9.3 UPC-10 
Tumor 0.22 +_0.05 a 0.08 ±0.01 
Blood 0.121 +0.02 b 0.162_+0.025 
Liver 0.023 ± 0.005 c 0.029 ± 0.006 
Mean % kg injected dose/g+ SEM (n = 5) 
























Fig. 4. Mean+_ S.E.M. tumor/non tumor ratios for specific 5F9.3 
and nonspecific UPC-10 antibody following subcutaneous foot pad 
(intralymphatic) administration with the animal killed 96 h later. 
Tumor/non tumor ratios for specific antibody are in all instances 
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Fig. 5. Tumor/blood ratios of specific (5F9.3) and nonspecific 
(UPC-10) antibodies following subcutaneous foot pad (intralym- 
phatic) injection to BEWO tumor bearing animals. Note strong 
correlation between tumor/blood ratios for specific (5F9.3) and 
non specific (UPC-10) antibodies given subcutaneously (intralym- 
phatic). Y= 10.41 X-3.242; R-squared: 0.93 
to specific antibody binding. The mean specific localization 
ratio was 3.6 4- 0.82 (SEM). Again, the specific localization 
ratio is significantly greater than one in these animals. The 
fraction of the injected dose reaching the tumor was always 
higher for the specific antibody than for the nonspecific 
antibody. This mirrors previous results following intrave- 
nous injection (Khazaeli et al. 1983). Note in Fig. 5 that 
as the tumor/blood ratios for specific antibody increased 
by the intralymphatic route, there was a significant parallel 
increase in the uptake of nonspecific antibody in a linear 
fashion (r = 0.93). This is in contrast to the lack of correla- 
tion between specific uptake to tumors following simulta- 
neous (intralymphatic) and intravenous injections of  131I 
and tzsI specific antibody (Fig. 3). 
Discussion 
The subcutaneous injection route was effective in demon- 
strating, by gamma camera scintigraphy, human derived 
choriocarcinoma tumors in the popliteal fossa ipsilateral 
to the subcutaneous injection site in the foot pad in our 
nude mouse model. Overall, a significant improvement in 
tumor/non tumor ratio was seen for the subcutaneous route 
of antibody delivery, as compared to the tumor/non tumor 
ratio achieved by intravenous antibody delivery. This im- 
provement is not just due to nonspecific trapping of protein 
in the lymph nodes or tumors, as was shown in double 
label coinjection experiments of specific and nonspecific an- 
tibody by the foot pad route. In these latter experiments 
there was a strong correlation between tumor accumulation 
of specific and nonspecific antibody, implying that similar 
factors may affect their nodal retention but indicating that 
the retention of specific antibody was invariably higher than 
that of  nonspecific antibody. Images of high quality were 
obtained at earlier time points than has been seen by intra- 
venous delivery of specific antibody (Khazaeli et al. 1983). 
Of additional importance is the fact that the improvement 
seen is in a tumor system of human origin using a mono- 
clonal antibody shown capable of localizing human tumors 
in man (Wahl et al. 1987). 
While some of these results are not totally unexpected, 
given the previous reports by Order, DeLand and Weinstein 
(Order et al. 1975; DeLand et al. 1980; Weinstein et al. 
1983), limited histology even on the smallest tumors in our 
series showed only lymphoid elements, but no discrete no- 
dal architecture. In fact, the average tumor in our series 
was 200fold larger than normal mouse popliteal lymph 
nodes. Thus, much of the node was totally replaced with 
tumor, yet improved localization was still seen by the subcu- 
taneous route. This route preferentially delivers antibody 
to the lymphatics due to their lack of a basement membrane 
(Weinstein et al. 1983). Thus, this delivery method appears 
to hold promise, even if nodal metastases are fairly substan- 
tial in size. This may be of particular clinical relevance to 
following enlarged lymph nodes posttherapy that are stable 
in size and thought to represent fibrosis, or even during 
therapy (Heiken et al. 1984). There was no clear relation- 
ship between tumor weight and tumor/blood ratios in this 
study. Certainly, some tumors must eventually become 
large enough that nodal lymph flow is impaired, but this 
may only occur with extremely large nodes. Our experience 
in lymphoscintigraphy of melanoma and that of others sug- 
gests this nodal obstruction is an infrequent occurrence 
(Eberbach et al. 1987). Certainly nodal obstruction can oc- 
cur and this can affect the results of colloidal lymphoscinti- 
grams (Ege 1983). It is possible that the mechanism of nodal 
uptake may vary between colloidal and noncolloidal agents 
(Wahl et al. 1986). 
Also of interest was the apparent dissociation between 
the tumor/blood ratios achieved by the intralymphatic and 
intravenous routes in the same tumors (Fig. 3). There was 
no correlation between specific antibody tumor/blood ra- 
tios following subcutaneous delivery and specific antibody 
tumor/blood ratios following intravenous administration in 
the coadministration studies. There was, however, a strong 
relationship between nodal uptake of specific antibody giv- 
en by the subcutaneous route and nonspecific antibody giv- 
en intralymphatically in this study ( r=  0.93). This suggests 
a basic difference in the mechanism of antibody uptake 
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for the two delivery routes. We know that both routes de- 
pend heavily on antibody specificity for uptake, but there 
appear to be some as yet unrecognized characteristics of 
certain tumors (such as a good lymphatic supply, but poor 
vascular supply or vice versa), that enhance delivery by 
one route over the other. Although the number of  animals 
studied is small, due to the relative difficulty of establishing 
the tumors in the popliteal fossa, the numbers were clearly 
adequate to delineate this strong relationship between the 
uptake ratios of  specific and nonspecific antibody adminis- 
tered by the subcutaneous route. 
Images obtained following subcutaneous delivery were 
generally considerably superior to those that have been seen 
previously in this tumor system by the intravenous route 
(Wahl et al. 1986). These improved tumor images were also 
seen at earlier time points by the subcutaneous delivery 
route than intravenously. This suggests that the optimum 
imaging time may be earlier for subcutaneously adminis- 
tered antibodies than for intravenously administered intact 
monoclonal antibodies. This, if verified in humans, will be 
useful in establishing a more prompt diagnostic study than 
the intravenous route of antibody delivery offers. 
In this series, the accretion of antibody to tumors fol- 
lowing subcutaneous administration was specific, as shown 
in double label experiments. Of interest was the fact that 
in the double label specific antibody studies, although there 
was a trend for higher quantities of the administered dose 
of antibody given subcutaneously to reach the tumor sites 
than for the same dose given intravenously, this did not 
achieve statistical significance. The improved tumor/blood 
ratios by the subcutaneous route were a statistically signifi- 
cant phenomenon, however. Also, in the tumor bearing ani- 
mals a lower proportion of the subcutaneously administered 
dose reached the blood, as compared with the intravenous 
route. These higher systemic antibody levels following intra- 
venous as compared with subcutaneous injection achieved 
statistical significance in the control BALB/c mice in whom 
the liver uptake following intravenous injection was signifi- 
cantly greater than that following subcutaneous injection. 
These lower systemic levels may be related to catabolism 
of antibodies by the tumor, the node, or subcutaneous tis- 
sues, to a greater extent when given subcutaneously than 
when given intravenously. One would expect that sustained 
release of antibody from the injection site might result in 
higher levels systemically at later time points. This was not 
the case. Since we did not kill animals at multiple time 
points, the reason for lower systemic antibody levels follow- 
ing subcutaneous administration is not yet resolved. 
The explanation for the higher tumor/non tumor ratios 
seen following subcutaneous administration is most likely 
related to a higher proportion of the injected dose reaching 
the tumor initially with an opportunity for improved first 
pass extraction. This is in contrast to intravenous delivery 
where many potential interactions of the antibody with non 
target antigens occur prior to the antibody reaching the 
tumor. I f  there is a high first pass clearance by tumor or 
normal nodes, then there would be a lower proportion of 
labeled antibody reaching the blood stream. This would 
account for a higher tumor/non tumor ratio and should 
also result in a higher total tumor uptake of radioantibody. 
Tumor uptakes tended to be higher by subcutaneous deliv- 
ery, but did not achieve statistical significance in the group 
of animals studied by simultaneous intravenous and subcu- 
taneous coinjection. Naturally, if catabolism or deiodina- 
tion occurred at the tumor, node, subcutaneous tissues, or 
in the lymphatics, then total nodal uptake might be lower 
or drop with time. The image data suggests that the radiola- 
beled antibody reached the popliteal tumors via the lym- 
phatic channels as in several cases the tumor were seen 
very early (e.g., Fig. 2c, d), prior to visualization of the 
rest of the animals blood pool without uptake seen in the 
intervening leg. Experiments recently performed with an- 
other IgG2a antibody given in the foot pad of normal rats 
has shown a less than two fold increase in activity in the 
muscle between the popliteal node and foot pad at four 
hours post injection, despite dramatically increased activity 
in the popliteal lymph node (Wahl et al. 1986). Thus, image 
data and tissue counting data do not lend support to the 
possibility that the phenomenon of increased uptake is due 
to diffusion of activity through muscle separate from lym- 
phatic flow to tumors in the popliteal region. We have also 
performed preliminary direct inratumoral injection of la- 
beled specific antibodies and have not seen the degree of 
increased tumor activity at delayed times seen by the subcu- 
taneous, and presumedly intralymphatic, methods (R. 
Wahl, unpublished data). Thus, our data favors the lym- 
phatics as the mode of delivering to the popliteal tumor 
much of the tumor imaging dose given subcutaneously. 
For imaging purposes, the higher tumor/non tumor ra- 
tios seen following subcutaneous injection will be beneficial. 
For therapy of tumor in the nodes, the problem of skin 
dose at the injection site needs to be addressed. Even with 
three days to clear the injected dose, in control animals 
the injected foot's activity is comparable to blood levels, 
indicating a significant radiation dose to the injection site 
(Table 1). 
In conclusion, the subcutaneous route of antibody deliv- 
ery offers significant advantages over the intravenous route 
in cases where there are tumor foci in or replacing lymph 
nodes draining the injection site. Tumor foci far larger than 
normal lymph nodes in this study had specific uptakes that 
were superior by the subcutaneous delivery route as com- 
pared to the intravenous route and the uptake in these tu- 
mors was largely due to antibody specificity as shown in 
dual label studies. Of note is that tumors that take up specif- 
ic antibody well by the subcutaneous route may not have 
similar superior uptake by the intravenous route and vice 
versa due to factors that are not yet fully defined, but most 
likely related to antibody access to tumor antigens. The 
subcutaneous delivery approach appears to be of value for 
human tumors including those that are larger than normal 
sized lymph nodes. This route of delivery warrants addition- 
al study in man. 
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